AbCellera Biologics Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 8QQ.F | VERA | CLDX | ACRS | 4583.T | 2142.HK | |
|---|---|---|---|---|---|---|
| Market cap | 3.48B | 2.20B | 2.25B | 560.97M | 6.73B | 9.31B |
| P/E (TTM) | — | — | — | — | — | 12.5 |
| Forward P/E | -358.0 | -7.1 | -6.8 | -5.0 | -2.8 | 12.0 |
| Price/book | 4.1 | 5.4 | 3.2 | 4.1 | 4.2 | 2.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +164.29% | +26.76% | +28.68% | +62.11% | −35.11% | −20.03% |
| Today | −3.24% | −4.60% | −4.06% | −1.64% | −2.35% | +5.62% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 8QQ.F news ›AbCellera Biologics (NASDAQ:ABCL) Stock Falls 7.7% – Should You Sell?
Posted by Kim Johansen on Nov 2nd, 2026 AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) shares were down 7.7% on Monday. The stock traded as low as $11.53 and last traded at $11.3290. Approximately 604,263 shares traded hands…
Critical Contrast: Agenus (NASDAQ:AGEN) versus AbCellera Biologics (NASDAQ:ABCL)
Posted by Kim Johansen on Nov 1st, 2026 Agenus (NASDAQ:AGEN – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses…
Wall Street Zen Upgrades AbCellera Biologics (NASDAQ:ABCL) to Hold
Posted by Tristan Rich on Oct 31st, 2026 AbCellera Biologics (NASDAQ:ABCL – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and…
Certain Common Stock of AbCellera Biologics Inc. are subject to a Lock-Up Agreement Ending on 13-OCT-2026.
www.marketscreener.com Certain Common Stock of AbCellera Biologics Inc are subject to a Lock-Up Agreement Ending on 13-OCT-2026 These Common Stock will be under lockup for 61 days starting fr
Transcript : AbCellera Biologics Inc. - Special Call
Presentation Operator MessageOperator Good afternoon, and welcome to the ABCL635 Phase II Clinical Update. My name is Jonathan, and I will facilitate the audio portion of today's interactive... Transcript : AbCellera Biologics Inc. -…
Abcellera Biologics Inc. Announces Collaboration with Vertex Pharmaceuticals Incorporated to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
AbCellera Biologics Inc. announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases... announced a collaboration with Vertex…
UBS Group Initiates Coverage on AbCellera Biologics (NASDAQ:ABCL)
Posted by Defense World Staff on Oct 12th, 2026 Research analysts at UBS Group assumed coverage on shares of AbCellera Biologics (NASDAQ:ABCL – Get Free Report) in a report released on Monday, Briefing.com reports. The brokerage set a…
Reviewing AbCellera Biologics (NASDAQ:ABCL) and Protagonist Therapeutics (NASDAQ:PTGX)
Posted by Defense World Staff on Oct 11th, 2026 Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) and AbCellera Biologics (NASDAQ:ABCL – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We…
Transcript : AbCellera Biologics Inc., Q2 2026 Earnings Call, Aug 05, 2026
Presentation Operator MessageOperator Good afternoon, and welcome to AbCellera's Q2 2026 Business Update Conference Call. My name is Jonathan, and I will facilitate the audio portion of today's... Transcript : AbCellera Biologics Inc., Q2…
AbCellera Biologics Inc.: Relative Strength Chart - Stock Nasdaq
Compare AbCellera Biologics Inc. with the company of your choice via a Relative Strength chart. Real-time ABCL price, Nasdaq stock exchange Relative Strength Chart AbCellera Biologics Inc. Biotechnology & Medical Research All financial…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com11
- themarketsdaily.com4
- defenseworld.net2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.